06678 百德醫療
BETTERS MED
BETTERS MED
| Listing Date | 2022/10/05 Suspended |
| Listing Price | 1.400 |
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Betters Medical Investment Holdings is one of the leading microwave ablation (MWA) medical device developers and providers in the PRC for minimally invasive treatment of tumours. Its proprietary MWA medical devices are used for treatment of benign and malignant tumours including thyroid nodules, liver cancer, lung cancer and breast lumps. Its pipeline products mainly consist of MWA therapeutic apparatus as well as MWA needles that are used in conjunction with the therapeutic apparatus.
According to Frost & Sullivan, the Group ranked first among MWA medical device providers in the treatment for thyroid nodules and breast lumps in the PRC in terms of sales revenue and sales volume of MWA needles in 2021. Further, it was the third largest MWA medical device provider in the PRC in terms of sales revenue in 2021.
The Group is the first company to have proprietary MWA medical devices specifically indicated for thyroid nodules registered as Class III medical devices. It possessed a total of 27 registered patents and 20 patents under application.
Its products are ultimately sold to hospitals were mostly Grade II and Grade III hospitals. For 5M2022, 259 hospitals in China procured its products, among which, 150 were Grade IIIA hospitals.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 2000 |
GLOBAL OFFERING
| No. of Offer Shares | 248.00M shares |
| No. of International Offer Shares | 202.92M shares |
| No. of HK Offer Shares | 45.08M shares |
| Offer Price | $1.40 - $1.72 |
| Stock Code | 6678 |
| Sponsor(s) | BOCI Asia Limited, Zhongtai International Capital Limited |
| Underwriter(s) | BOCI Asia Limited, Zhongtai International Securities Limited, China Galaxy International Securities (Hong Kong) Co., Limited, Cinda International Capital Limited, Huatai Financial Holdings (Hong Kong) Limited, Eddid Securities and Futures Limited, China Everbright Securities (HK) Limited, Guosen Securities (HK) Capital Company Limited, China Industrial Securities International Capital Limited, Valuable Capital Limited, ZMF Asset Management Limited |
TIME TABLE
| Application Period | Sep 22 (Thu) - noon, Sep 27 (Tue) |
| Price Determination Date | Sep 27 (Tue) |
| Result Announcement Date | On or before Oct 03 (Mon) |
| Result Announcement Date | On or before Oct 03 (Mon) |
| Dealings in Shares commence on | Oct 05, 2022. (Wed) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $1.40 - $1.72 |
| Capitalization | 2.24B - 2.75B |
| NAV / share ($) | $0.29 - $0.34 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 1.56, the net proceeds raised would be HKD 300.20M, of which |
| 41% : Broadening and deepening product portfolio, upgrading medical licences and expanding R&D team |
| 38% : Pursuing strategic acquisitions, investment or synergistic business cooperation |
| 8% : Expanding its presence in foreign and emerging markets by setting up overseas offices |
| 3% : Acquiring automated machineries and equipment to improve the automation level of production lines |
| 10% : Working capital |
IPO NEWS
| 03/10/2022 18:35 |
| {New Stock}BETTERS MED ends down 40.71% on grey market |
| 03/10/2022 16:20 |
| {New Stock}BETTERS MED down 28.57% at HK$1 on grey market |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).